Biomea Fusion to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Biomea Fusion (Nasdaq: BMEA), a clinical-stage biopharmaceutical company focused on developing oral covalent small molecules for diabetes, obesity, and genetically defined cancers, has announced its participation in the 43rd Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Biomea Fusion (Nasdaq: BMEA), a clinical-stage biopharmaceutical company focused on developing oral covalent small molecules for diabetes, obesity, and genetically defined cancers, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference.
Thomas Butler, CEO and Board Chairman, will deliver a presentation on Wednesday, January 15, 2025, at 1:30 PM PT / 4:30 PM ET. The company's management team will also conduct one-on-one meetings throughout the conference, which runs from January 13 to January 16.
Interested parties can access a live audio webcast of the presentation through the company's investor relations website at investors.biomeafusion.com/news-events/events, with a replay available after the live presentation.
Details
News Market Reaction – BMEA
The recorded move for BMEA in the trading session of this news was +5.09%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with diabetes, obesity, and genetically defined cancers, today announced today that Thomas Butler, Chief Executive Officer and Chairman of the Board, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 1:30 PM Pacific Time / 4:30 PM Eastern Time. Additionally, Biomea’s management team will be hosting one-on-one meetings throughout the conference, taking place from January 13 to January 16.
A live audio webcast of the presentation can be accessed here or by visiting the Investors & Media section of Biomea’s website at https://investors.biomeafusion.com/news-events/events. A replay of the webcast will be available following the live presentation.
About Biomea Fusion
Biomea Fusion is a clinical-stage biopharmaceutical company focused on the discovery and development of oral covalent small molecules to improve the lives of patients with diabetes, obesity, and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs, including greater target selectivity, lower drug exposure, and the ability to drive a deeper, more durable response.
We are utilizing our proprietary FUSION™ System to discover, design and develop a pipeline of next-generation covalent-binding small-molecule medicines designed to maximize clinical benefit for patients. We aim to significantly improve disease treatments for the patients we serve. We aim to cure.
Visit us at biomeafusion.com and follow us on LinkedIn, X and Facebook.
Contact:
Ramses Erdtmann
COO & President of Biomea Fusion
re@biomeafusion.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.